Chronic Plaque Psoriasis Market is anticipated to surge due to an increasingly prevalent population of Plaque Psoriasis, the expected launch of emerging drugs, as well as entry of many key pharmaceuticals such as Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, and others are driving the Chronic Plaque Psoriasis Market.
DelveInsight’s “Chronic Plaque Psoriasis Market Insight” report provides a thorough comprehension of the Chronic Plaque Psoriasis historical and forecasted epidemiology and the Chronic Plaque Psoriasis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Chronic Plaque Psoriasis market report also proffers an analysis of the current Chronic Plaque Psoriasis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis is a chronic inflammatory skin disease characterised by well demarcated, erythematous, scaly plaques on the extensor surfaces of the body and scalp.
Chronic Plaque Psoriasis Epidemiology
DelveInsight estimates that the total psoriasis prevalent population in 7MM was 15,450,712 cases in 2020. Also, psoriasis affects both males and females equally.
The Chronic Plaque Psoriasis Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:
- Prevalence of Psoriasis (Adults and Pediatrics)
- Chronic Plaque Psoriasis Prevalence
- Prevalence of Chronic Plaque Psoriasis by Severity
- Diagnosed and Treatable Cases of Chronic Plaque Psoriasis
Some of the necessary takeaways from the Chronic Plaque Psoriasis Market Research Report
- Several key pharmaceutical companies including Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, Dr. Reddy’s Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Akros Pharma, Affibody AB, and others, are developing novel products to improve the Chronic Plaque Psoriasis treatment outlook.
- In October 2020, Leo Pharma announced that the US FDA approved a US Prescribing Information (USPI) update for Enstilar (calcipotriene and betamethasone dipropionate) foam to include data on long-term use in adults with plaque psoriasis.
- In July 2020, MC2 Therapeutics announced that the USFDA approved Wynzora Cream for once-daily topical plaque psoriasis treatment in adults 18 years of age or older.
- In September 2020, UCB announced that the FDA had accepted the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.
For further information on Market Impact by Therapies, visit: Chronic Plaque Psoriasis Drugs Market Analysis
Chronic Plaque Psoriasis Treatment Market
A range of agents is available for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis usually receive topical treatments. These cases can be treated topically with glucocorticoids, vitamin D analogs, and phototherapy.
Major topical treatments for Chronic Plaque Psoriasis include corticosteroids, retinoids such as tazarotene, calcineurin inhibitors such as tacrolimus, vitamin D analogs such as calcipotriene or calcitriol, and combinations such as calcipotriol plus betamethasone dipropionate.
Biologics have emerged as highly potent Chronic Plaque Psoriasis treatment options in patients for whom traditional systemic therapies fail to achieve an adequate response, are not tolerated owing to adverse effects, or are unsuitable due to comorbidities.
Due to its superior safety and efficacy profile, Adalimumab has become the therapy of choice for severe psoriasis. There are now several biosimilars approved to treat psoriasis and Psoriatic Arthritis.
The Chronic Plaque Psoriasis Pipeline scenario shows early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for psoriasis are in development, many of which have novel targets and mechanisms of action. Bimekizumab (UCB) is in the late development stages among biologics. Apart from this, Sonelokimab (Merck) and Vunakizumab (Hengrui Therapeutics) are currently in the phase II stage of clinical development.
Talking about oral Psoriasis treatment, there are many candidates in the different stages of development. Deucravacitinib (Bristol Myers Squibb) is a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor for treating patients with moderate to severe plaque psoriasis. Furthermore, there are few oral candidates such as BI 730357 (Boehringer Ingelheim), JTE-451 (Akros Pharma Inc.), KD025 (Kadmon Pharmaceuticals), PF-06826647 (Pfizer), and XP23829 (Arbor Pharmaceuticals/Dr. Reddy’s Laboratories) in phase II stage of clinical development.
There are plenty of treatment options available for psoriasis patients; however, each has some potential shortcomings, such as side effects and high costs. To combat these issues, many therapies are currently under different stages of clinical development, which in turn shall fuel the Chronic Plaque Psoriasis market growth during the forecast period (2021–2030).
Scope of the Chronic Plaque Psoriasis Market Insight Report
- Study Period: 2019-32
- Geography Covered: 7MM
- Key Chronic Plaque Psoriasis Companies: Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, Dr. Reddy’s Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Akros Pharma, Affibody AB, and several others.
- Key Chronic Plaque Psoriasis Pipeline Therapies: Bimekizumab, Sonelokimab, Vunakizumab, Deucravacitinib, BI 730357, JTE-451, KD025, PF-06826647, XP23829, Enstilar, Wynzora Cream
- Chronic Plaque Psoriasis Therapeutic Assessment: Current marketed and emerging therapies
- Chronic Plaque Psoriasis Market Dynamics: Market drivers and barriers
- Comparative and conjoint analysis of emerging therapies, Case Studies, KOL’s Views, Analyst’s View
Request for a Webex demo of the report @ Chronic Plaque Psoriasis Therapeutics Market
Table of Contents
| 1 | Chronic Plaque Psoriasis Key Insights |
| 2 | Chronic Plaque Psoriasis Report Introduction |
| 3 | Chronic Plaque Psoriasis Market Overview at a Glance |
| 4 | Executive Summary of Chronic Plaque Psoriasis |
| 5 | Chronic Plaque Psoriasis Disease Background and Overview |
| 6 | Chronic Plaque Psoriasis Epidemiology and Patient Population |
| 7 | Country Wise-Epidemiology of Chronic Plaque Psoriasis |
| 7.1 | The United States |
| 7.2 | EU5 Countries |
| 7.2.1 | Germany |
| 7.2.2 | France |
| 7.2.3 | Italy |
| 7.2.4 | Spain |
| 7.2.5 | The United Kingdom |
| 7.3 | Japan |
| 8 | Organizations contributing towards Chronic Plaque Psoriasis |
| 9 | Chronic Plaque Psoriasis Case Reports |
| 10 | Chronic Plaque Psoriasis Patient Journey |
| 11 | Chronic Plaque Psoriasis Marketed Therapies |
| 12 | Chronic Plaque Psoriasis Emerging Therapies |
| 13 | Chronic Plaque Psoriasis 7MM Market Analysis |
| 13.1 | The United States Chronic Plaque Psoriasis Market Size |
| 13.2 | EU-5 Chronic Plaque Psoriasis Market Size |
| 13.2.1 | Germany Market Size |
| 13.2.2 | France Market Size |
| 13.2.3 | Italy Market Size |
| 13.2.4 | Spain Market Size |
| 13.2.5 | The United Kingdom Market Size |
| 13.2.3 | Japan Chronic Plaque Psoriasis Market Size |
| 14 | Chronic Plaque Psoriasis Market Drivers |
| 15 | Chronic Plaque Psoriasis Market Barriers |
| 16 | Chronic Plaque Psoriasis SWOT Analysis |
| 17 | Chronic Plaque Psoriasis Unmet Needs |
| 18 | Chronic Plaque Psoriasis KOL Views |
| 19 | Appendix |
| 20 | DelveInsight Capabilities |
| 21 | Disclaimer |
| 22 | About DelveInsight |
Browse full report with detailed TOC with charts, figures, tables @ Chronic Plaque Psoriasis Diagnostics Market Report
View Other Reports
DelveInsight’s Chronic Plaque Psoriasis – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Chronic Plaque Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
“Chronic Plaque Psoriasis Pipeline Insights, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across 7MM. Key players involved in this market are Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, BMS, Merck, UCB Pharma, Arbor Pharmaceuticals, Dr. Reddy’s Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Akros Pharma, Affibody AB, and others.
DelveInsight’ s Psoriasis – Market Insights, Epidemiology and Market Forecast – 2032 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.
DelveInsight’ s Severe Psoriasis – Market Insights, Epidemiology and Market Forecast – 2032 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.
Other Reports:
NCFB Market | Metastatic Bone Pain Market | Ventricular Hypertrophy Market | Diagnostic Imaging Equipment Market | Invasive Candidiasis Market | Upper Limb Hypertonia Market | Sialidosis Market | Filgrastim Biosimilar Insight | 3D Cardiac Mapping System Market | Acanthamoeba Keratitis Market | Adult Growth Hormone Deficiency Market | Advanced Cancer Pain Management Market | Apheresis Market | Arteriovenous fistula Market | Automated external defibrillators (AEDs) Market | Balloon Catheters Market | Calciphylaxis Market | Cerebral Aneurysm Market | Chronic Idiopathic Urticaria Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Contact Us:
Shruti Thakur
+1(919)321-6187